Iptacopan

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 142 publications

Iptacopan in IgA Nephropathy - Final 24-Month Data.

Iptacopan in IgA Nephropathy - Final 24-Month Data.

Journal: The New England journal of medicine

Published: March 30, 2026

Case report: persistent anemia after eculizumab in paroxysmal nocturnal hemoglobinuria: non-dominantly active intravascular hemolysis.

Case report: persistent anemia after eculizumab in paroxysmal nocturnal hemoglobinuria: non-dominantly active intravascular hemolysis.

Journal: Hematology (Amsterdam, Netherlands)

Published: March 20, 2026

Indirect treatment comparison of iptacopan versus pegcetacoplan for patients with paroxysmal nocturnal hemoglobinuria and residual anemia despite C5 inhibitor treatment.

Indirect treatment comparison of iptacopan versus pegcetacoplan for patients with paroxysmal nocturnal hemoglobinuria and residual anemia despite C5 inhibitor treatment.

Journal: Journal of comparative effectiveness research

Published: March 19, 2026

Complement biomarkers during iptacopan treatment - Authors' reply.

Complement biomarkers during iptacopan treatment - Authors' reply.

Journal: Lancet (London, England)

Published: February 12, 2026

Complement 3 Glomerulopathy Revisited: Bridging Pathogenesis and Therapy in the New Era.

Complement 3 Glomerulopathy Revisited: Bridging Pathogenesis and Therapy in the New Era.

Journal: Advances in kidney disease and health

Published: February 11, 2026

Switching patients with PNH from pegcetacoplan to iptacopan: a case series.

Switching patients with PNH from pegcetacoplan to iptacopan: a case series.

Journal: Hematology (Amsterdam, Netherlands)

Published: February 09, 2026

Practical Considerations for Infection Prevention with the Clinical Use of Complement Inhibitors.

Practical Considerations for Infection Prevention with the Clinical Use of Complement Inhibitors.

Journal: Clinical journal of the American Society of Nephrology : CJASN

Published: February 06, 2026

Early Experience With Iptacopan for Recurrent IgA Nephropathy After Kidney Transplantation.

Early Experience With Iptacopan for Recurrent IgA Nephropathy After Kidney Transplantation.

Journal: Kidney medicine

Published: January 29, 2026

Improvement in anemia and symptoms after switching from crovalimab to iptacopan in paroxysmal nocturnal hemoglobinuria.

Improvement in anemia and symptoms after switching from crovalimab to iptacopan in paroxysmal nocturnal hemoglobinuria.

Journal: Hematology (Amsterdam, Netherlands)

Published: January 29, 2026

IgA Nephropathy in Adults: A Review.

IgA Nephropathy in Adults: A Review.

Journal: JAMA

Published: January 26, 2026

Advancing treatment goals for paroxysmal nocturnal hemoglobinuria to align with quality of life improvements in the era of anti-complement therapy

Advancing treatment goals for paroxysmal nocturnal hemoglobinuria to align with quality of life improvements in the era of anti-complement therapy

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: January 12, 2026

Cost per responder analysis of iptacopan versus eculizumab and ravulizumab in treatment of paroxysmal nocturnal hemoglobinuria: implications for decision-making.

Cost per responder analysis of iptacopan versus eculizumab and ravulizumab in treatment of paroxysmal nocturnal hemoglobinuria: implications for decision-making.

Journal: Journal of medical economics

Published: January 10, 2026

Showing 1-12 of 142

Last Updated: 04/28/2026